FINWIRES · TerminalLIVE
FINWIRES

$MRNA

98 stories mentioning MRNAUpdated 4d ago

Every FINWIRES story that references MRNA, newest first.

What are analysts saying about MRNA?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on MRNA?

Wire

Market Chatter: Moderna's Flu Shot Wins Support From FDA Advisers

Moderna's (MRNA) influenza vaccine for adults 50 and older received a recommendation for approval from outside advisers to the US Food and Drug Administration, Bloomberg reported Thursday, citing a unanimous vote by the agency's Vaccines and Related Biological Products Advisory Committee.The recommendation for the mRNA-based shot is nonbinding, though the FDA typically follows its advisory panels, the report said.Moderna did not immediately respond to' request for comment.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $64.26, Change: $+2.46, Percent Change: +3.98%

$MRNA
Asia Markets

Update: US Equity Indexes Drop as Bets for Higher Interest Rates Jump After Fed Eliminates Easing Bias

(Updates with index/price moves, FedWatch outlook, macro data, and political/company news from the first paragraph.)US equity indexes fell while government bond yields jumped as odds favoring higher interest rates this year surged after the Federal Reserve removed the so-called easing bias from its policy statement.The Nasdaq Composite fell 1.4% to 26,021.66, with the S&P 500 down 1.2% to 7,420.10 and the Dow Jones Industrial Average lower by 1% to 51,492.55 on Wednesday. All sectors fell, with communication services, consumer discretionary, and consumer staples leading the decliners at the close.The Fed left its benchmark rate unchanged in the 3.50% to 3.75% range in a unanimous decision announced Wednesday, excluding language that suggested a lingering bias toward cuts."Economic activity is expanding at a solid pace despite elevated uncertainty that owes, in part, to the conflict in the Middle East," the Fed statement said. "Job gains have kept pace with the workforce, and the unemployment rate has changed little."The probability of a 25-basis-point increase in rates to a target range of 3.75% to 4% in July soared to 35% from 9% a day ago, according to the CME FedWatch tool. The comparisons for September were 47% versus 27%, and, for October, the data showed an increase to 45% from 33%. Strikingly, there is a 33% likelihood that rates will be 4% to 4.25% in December, implying that the Fed may raise rates by another 25 basis points even after tightening policy once between July and October.In economic news, retail sales climbed 0.9% after a downwardly revised 0.4% gain in April, the Census Bureau reported Wednesday. The consensus was for a 0.6% increase in May, based on a Bloomberg survey.Pending home sales rose by 3.8% in May, above the 0.9% increase expected in a survey compiled by Bloomberg and following a 0.3% increase in April, according to the National Association of Realtors. The monthly sales index was up 4.8% from a year ago.US Treasury yields jumped, with the 10-year surging 6.1 basis points to 4.49% and the two-year soaring 14.8 basis points to 4.2%.In geopolitical news, the US draft of the framework agreement with Iran includes a new 'minimum' standard for diluting Iran's uranium and toll-free passage of the Strait of Hormuz for 60 days, senior US officials told the Associated Press. That shows the US draft does not preclude Iran from imposing fees on maritime traffic after the fixed period.The US draft includes provisions to ensure "territorial integrity" of Lebanon after Israel's latest attacks in the country against the militant outfit Hezbollah, the officials were cited as saying. In return, the US will waive, but not eliminate, some sanctions that were previously imposed on Iran after the deal is signed on Friday, the news report said, adding that Tehran has not released its version of the peace deal.In his closing remarks at the G7 summit in France, French President Emmanuel Macron said that it is vital that Iran, Hezbollah, and Israel do not resume fighting, while noting that Paris supports a preliminary US-Iran deal to end the war, according to CNN.Front-month global benchmark North Sea Brent slipped 0.1% to $78.85 per barrel, and US West Texas Intermediate edged 0.2% lower to $75.92 per barrel.In company news, Moderna (MRNA) plans to invest in production sites in Germany and is interested in the plants that BioNTech (BNTX) has slated for closure, according to a Google translation of a Wednesday report published by German news outlet Handelsblatt. Shares of the COVID vaccine manufacturer soared 12%, the biggest outperformer on the S&P 500.

Dow JonesNasdaq CompositeS&P 500$MRNA
International

US Equity Markets End Lower After Government Bond Yields Rise, Fed's Policy Statement

US equity indexes were lower on Wednesday as government bond yields rose and the Federal Reserve announcement excluded any language hinting at near-term rate cuts.* "Economic activity is expanding at a solid pace despite elevated uncertainty that owes, in part, to the conflict in the Middle East," the Fed statement said. "Job gains have kept pace with the workforce, and the unemployment rate has changed little."* Iran accused Israel of violating the truce in Lebanon 84 times since it reached the interim agreement with the US and warned of a "harsh response" if attacks continue, Al Jazeera reported.* July West Texas Intermediate crude oil fell $0.10 to settle at $75.95 per barrel, while August Brent crude, the global benchmark, was last seen down $0.08 at $78.87.* Moderna (MRNA) plans to invest in production sites in Germany and is interested in the plants that BioNTech (BNTX) has slated for closure, according to a Google translation of a Wednesday report from German news outlet Handelsblatt. Moderna shares were up roughly 12%, the top gainer on the S&P 500, and BioNTech stock was up about 2.9%.* Carvana (CVNA) shares were down nearly 10%, the worst performer on the S&P 500, after competitor CarMax's (KMX) fiscal Q1 earnings fell year over year on Wednesday as comparable used vehicle sales swung negative and its management flagged higher margin pressure in the near term.

Dow JonesNasdaq CompositeS&P 500$BNTX$CVNA$KMX$MRNA
Sectors

Sector Update: Healthcare Stocks Retreat Late Afternoon

Healthcare stocks declined late Wednesday afternoon, with the NYSE Healthcare Index falling 1.3% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 1.8%.The iShares Biotechnology ETF (IBB) rose 0.7%.In corporate news, ResMed (RMD) shares fell 4.5% after Morgan Stanley downgraded the company to equalweight from overweight and cut its price target to $230 from $286.UniQure (QURE) shares surged 76% after the company said that it intends to submit a Biologics License Application for the accelerated approval of AMT-130 to treat Huntington's disease in Q3.Novo Nordisk (NVO) said it is aware of claims by cyber extortion group FulcrumSec that it stole company data and sought a $25 million payment, Reuters reported. Novo shares were up 0.2%.Moderna (MRNA) plans to invest in production sites in Germany and is interested in the plants that BioNTech (BNTX) has slated for closure, according to a Google translation of a Wednesday report from German news outlet Handelsblatt. Moderna shares jumped almost 11%, and BioNTech was up 2.3%.

$BNTX$MRNA$NVO$QURE$RMD
Wire

Sector Update: Healthcare Stocks Decline Wednesday Afternoon

Healthcare stocks declined Wednesday afternoon, with the NYSE Healthcare Index decreasing 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 0.7%.The iShares Biotechnology ETF (IBB) rose 2.2%.In corporate news, IQVIA (IQV) shares fell 3.3% after Morgan Stanley downgraded the company to equalweight from overweight and cut its price target to $200 from $225.Novo Nordisk (NVO) said it is aware of claims by cyber extortion group FulcrumSec that it stole company data and sought a $25 million payment, Reuters reported. Novo shares were up 1.8%.Moderna (MRNA) plans to invest in production sites in Germany and is interested in the plants that BioNTech (BNTX) has slated for closure, according to a Google translation of a Wednesday report from German news outlet Handelsblatt. Moderna shares jumped past 8%, and BioNTech was up 4%.

$BNTX$IQV$MRNA$NVO
International

US Equity Markets End Mixed as Dow Hits Record High Amid Lower Crude Oil Prices, Tech Stock Sell-Off

US equity indexes were mixed on Tuesday after the Dow Jones Industrial Average hit a new all-time intraday amid sliding crude oil prices, while technology stocks witnessed a sell-off.* Iran warned that any Israeli attack on Lebanon or continued occupation of its territory from now on will constitute a violation of the interim agreement with the US, Al Jazeera reported. However, Israeli Prime Minister Benjamin Netanyahu has made clear he does not intend to withdraw from southern Lebanon, Gaza, or Syria, according to the CNN news report.* US import prices jumped 1.9% in May, ahead of the 1% increase expected in a Bloomberg-compiled survey and following a 2.0% gain in April.* Redbook US same-store sales soared 9.4% from a year earlier in the week ended June 13, after surging 9.1% in the previous week.* July West Texas Intermediate crude oil fell $3.81 to settle at $76.94 per barrel, while August Brent crude, the global benchmark, was last seen down $3.47 at $79.70.* Moderna (MRNA) shares were up about 6.3%, the second-best gainer on the S&P 500, after the company said Tuesday it is changing the corporate operating model to support short and long-term business goals.* Marvell Technology (MRVL) shares fell nearly 10%, the steepest decline on the S&P 500, a day after outgoing CFO Willem Meintjes filed to sell 211,329 shares, according to Form 144 filings with the US Securities and Exchange Commission.

Dow JonesNasdaq CompositeS&P 500$MRNA$MRVL
Sectors

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks rose late Thursday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding about 0.7%.The iShares Biotechnology ETF (IBB) was up 0.8%.In corporate news, West Pharmaceutical Services (WST) shares rose 3.1% after the company said it has restored its core enterprise systems following a recent cybersecurity attack.Eli Lilly (LLY) shares added 2.6% after the company said its investigational retatrutide delivered "clinically meaningful" weight loss in a phase 3 trial, where all doses met the primary and key secondary endpoints at 80 weeks.Hims & Hers Health (HIMS) said Thursday that it has launched generic semaglutide for eligible customers in Canada. Its shares gained 2.7%.Moderna's (MRNA) experimental flu shot made with mRNA technology will be reviewed by a Food and Drug Administration advisory panel on June 18, Bloomberg reported. Moderna shares were down 1.5%.

$HIMS$LLY$MRNA$WST
Sectors

Sector Update: Healthcare Stocks Rise Thursday Afternoon

Healthcare stocks rose Thursday afternoon, with the NYSE Healthcare Index increasing 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.5%.The iShares Biotechnology ETF (IBB) was up 0.6%.In corporate news, Eli Lilly (LLY) shares rose 2.1% after the company said its investigational retatrutide delivered "clinically meaningful" weight loss in a phase 3 trial, where all doses met the primary and key secondary endpoints at 80 weeks.Hims & Hers Health (HIMS) said Thursday that it has launched generic semaglutide for eligible customers in Canada. Its shares popped 3.3%.Moderna's (MRNA) experimental flu shot made with mRNA technology will be reviewed by a Food and Drug Administration advisory panel on June 18, Bloomberg reported. Moderna shares were down 1.5%.

$HIMS$LLY$MRNA
Wire

Market Chatter: Moderna's Experimental Flu Shot to Be Reviewed by FDA Panel in June

Moderna's (MRNA) experimental flu shot made with mRNA technology will be reviewed by a Food and Drug Administration advisory panel on June 18, Bloomberg reported Thursday, citing a notice.The FDA is expected to make a decision on whether to approve the vaccine by Aug. 5, the report said.Moderna didn't immediately reply to a request for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $46.71, Change: $-1.42, Percent Change: -2.94%

$MRNA
Wire

Moderna's Experimental Flu Shot to be Reviewed by FDA Panel in June, Bloomberg Reports

Moderna's Experimental Flu Shot to be Reviewed by FDA Panel in June, Bloomberg Reports

$MRNA
Sectors

Sector Update: Healthcare Stocks Softer Late Afternoon

Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index down 0.3% and the State Street Healthcare Select Sector SPDR ETF (XLV) declining 0.4%.The iShares Biotechnology ETF (IBB) was little changed.In corporate news, Zoetis (ZTS) shares fell 7.5% after BNP Paribas cut its price target to $146 from $185, following the company's Q1 results late last week.Moderna (MRNA) has been working on early-stage vaccines targeting hantaviruses, Bloomberg reported Friday, citing a company statement. The research began before recent infections were reported aboard the Dutch-flagged Hondius, the report said. Moderna shares fell 3.7%.Sonida Senior Living (SNDA) shares fell 3.3% after the company reported Q1 loss of $2.39 per diluted share, widening from the loss of $0.77 a year earlier. Analysts polled by FactSet expected a loss of $1.53.Erasca (ERAS) entered into a clinical trial collaboration and supply agreement with Merck (MRK) to study its investigational drug ERAS-0015 in combination with Keytruda in patients with RAS-mutant solid tumors. Erasca shares rose 3%.

$ERAS$MRNA$SNDA$ZTS
Sectors

Sector Update: Healthcare Stocks Mixed in Afternoon Trading

Healthcare stocks were mixed Monday afternoon with the NYSE Healthcare Index rising 0.2% and the State Street Healthcare Select Sector SPDR ETF (XLV) little changed, paring earlier losses.The iShares Biotechnology ETF (IBB) increased 0.3%.In corporate news, Moderna (MRNA) has been working on early-stage vaccines targeting hantaviruses, Bloomberg reported Friday, citing a company statement. The research began before recent infections were reported aboard the Dutch-flagged Hondius, the report said. Moderna shares fell 2.2%.Sonida Senior Living (SNDA) shares fell 3.6% after the company reported Q1 loss of $2.39 per diluted share, widening from the loss of $0.77 a year earlier. Three analysts polled by FactSet expected a loss of $1.53.Erasca (ERAS) entered a clinical trial collaboration and supply agreement with Merck (MRK) to study its investigational drug ERAS-0015 in combination with Keytruda in patients with RAS-mutant solid tumors. Erasca shares rose 3.3%, and Merck added 1.2%.

$ERAS$MRK$MRNA$SNDA
Research

Research Alert: CFRA Keeps Hold View On Shares Of Moderna; Shares +16% Amid Andes Outbreak

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:MRNA shares rose over 16% in five days following an Andes virus (rare hantavirus strain) outbreak on cruise ship MV Hondius. The vessel, carrying ~150 passengers from 23 countries, departed Argentina on April 1 and docked in the Canary Islands on May 10 with six confirmed cases, two probable cases, and three deaths. While no hantavirus vaccine currently exists, mRNA technology offers advantages including rapid development, strain adaptability, and stronger immune response versus traditional vaccines. Moderna is developing an mRNA hantavirus vaccine with Korea University, though the program remains in early preclinical stages (animal studies only), suggesting substantial time is needed despite current market enthusiasm. Health officials assess the pandemic risk as low given the virus requires close, prolonged contact for transmission. The Andes virus is the only known hantavirus strain to spread person-to-person. We raise our target to $58 from $48 based on NPV analysis, maintain our 2026 LPS at -$7.95, and keep 2027 LPS at -$4.82.

$MRNA
Wire

Top Midday Stories: Moderna Working on Hantavirus Vaccine, Shares Rise; Blackstone, Halliburton to Invest Combined $1 Billion in VoltaGrid

The three major US stock indexes were up slightly in late-morning trading Monday after President Donald Trump said Sunday on Truth Social that he has rejected Iran's latest proposal to end the war.In company news, Moderna (MRNA) said it has been working on early-stage vaccines targeting hantaviruses, Bloomberg reported. The research began before recent infections were reported aboard the Dutch-flagged Hondius, the report said, citing the company. Moderna shares were up 4.9% around midday.Blackstone (BX) and Halliburton (HAL) will invest a combined $1 billion into energy startup VoltaGrid in a deal that values the company at over $10 billion, Bloomberg reported Monday, citing people familiar with the matter. Separately, Blackstone agreed to acquire a majority stake in Greek online marketplace Skroutz from CVC Capital Partners, Bloomberg reported Monday. Financial terms of the deal were not disclosed, though people familiar with the matter reportedly told Bloomberg it values Skroutz at 635 million euros. Lastly, Blackstone Real Estate Debt Strategies has launched a lending platform to provide capital and flexibility to US homebuilders, the company said Monday. Blackstone shares were down 1.0%, while Halliburton shares were up 0.6%.Cerebras Systems is planning to increase the size and price of its initial public offering, the company said in a regulatory filing. Cerebras plans to raise its IPO price to a range of $150 to $160 per share from $115 to $125 per share and increase the number of shares marketed to 30 million from 28 million.Apollo Global Management (APO) said Monday its managed funds signed definitive agreements to buy Emerald Holding (EEX) and Questex to form a combined business events platform. The company will pay $5.03 per share to acquire Emerald, assigning the target company an expected value of about $1.50 billion, the company said. Separately, Apollo is in talks to sell its MidCap Financial Investment (MFIC) business development company, The Wall Street Journal reported Sunday, citing people familiar with the matter. Apollo values the business at around $3 billion, the report said, citing the sources. Apollo shares were down 0.8%, while Emerald shares were up 9.3% and MidCap shares were down 2.6%.FS KKR Capital (FSK) reported a Q1 loss Monday of $1.57 per diluted share. Total Q1 investment income was $304 million down from $400 million a year ago and below the FactSet consensus analyst estimate of $316.8 million. The company said Monday that KKR's (KKR) KKR Alternative Assets unit will launch a tender offer to buy up to $150 million of FS KKR Capital's shares at $11 each. The offering will begin Tuesday and is expected to expire on June 9, the company said. KKR Alternative Assets agreed to buy $150 million in newly issued shares of cumulative convertible perpetual preferred stock, FS KKR Capital said Sunday. FS KKR shares were up 0.5%, while KKR shares were down 2.8%.Alphabet (GOOG, GOOGL) on Monday filed a preliminary prospectus supplement with the SEC for a multi-tranche yen-denominated bond offering targeting qualified institutional investors in Japan. The offering consists of five series of notes with varying maturities and interest rates, with all payments to be made in Japanese yen, the filing said. Alphabet's Class C and Class A shares were down 1.8% and 1.9%, respectively.Walt Disney's (DIS) ABC network has been the victim of "sustained, coordinated" censorship by the Trump administration, Federal Communications Commissioner Anna Gomez said in a letter to Disney Chief Executive Josh D'Amaro, The Wall Street Journal reported Monday, citing the letter, which it viewed. Disney shares were down 2.0%.Price: $54.87, Change: $+0.52, Percent Change: +0.95%

$APO$BX$DIS$EEX$FSK$GOOG$GOOGL$HAL$KKR$MFIC$MRNA
Sectors

Sector Update: Healthcare Stocks Rise Premarket Monday

Healthcare stocks were rising premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.2% higher and the iShares Biotechnology ETF (IBB) up 0.4%.Moderna (MRNA) stock was up more than 8% after the company, according to Bloomberg, said it has been working on early stage vaccines targeting hantaviruses.Liquidia (LQDA) shares were up more than 3% after the company said it swung to Q1 earnings as revenue rose during the period.Zai Lab (ZLAB) received the US Food and Drug Administration's fast track designation for zocilurtatug pelitecan, or zoci, for the treatment of extrapulmonary neuroendocrine carcinomas, the company said. Zai Lab stock was up nearly 4% pre-bell.

$IBB$LQDA$MRNA$XLV$ZLAB
Commodities

Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Monday as Trump Rejects Reported Iran Proposal

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.1% and the actively traded Invesco QQQ Trust (QQQ) was 0.03% higher in Monday's premarket activity as US President Donald Trump rejected Iran's reported resolution offer.US stock futures were mixed, with S&P 500 Index futures down 0.1%, Dow Jones Industrial Average futures slipping 0.2%, and Nasdaq futures gaining 0.03% before the start of regular trading.The existing home sales data for April will be released at 10 am ET.In premarket activity, bitcoin was down by 0.3%. Among cryptocurrency ETFs, the cryptocurrency fund ProShares Bitcoin Strategy ETF (BITO) was 1.1% higher, Ether ETF (EETH) advanced 0.9%, and Bitcoin & Ether Market Cap Weight ETF (BETH) gained 2.8%.Power Play:TechnologyThe State Street Technology Select Sector SPDR ETF (XLK) advanced by 0.4%, and the iShares US Technology ETF (IYW) was 0.5% higher, while the iShares Expanded Tech Sector ETF (IGM) was up 0.6%. Among semiconductor ETFs, the State Street SPDR S&P Semiconductor ETF (XSD) increased by 2.6%, while the iShares Semiconductor ETF (SOXX) rose by 0.9%.Monday.com (MNDY) shares were up more than 24% in premarket activity after the company reported higher Q1 adjusted earnings and revenue.Winners and Losers:Health CareThe State Street Health Care Select Sector SPDR ETF (XLV) advanced 0.2%, the Vanguard Health Care Index Fund (VHT) retreated by 0.2%, while the iShares US Healthcare ETF (IYH) slipped 0.7%. The iShares Biotechnology ETF (IBB) was flat.Moderna (MRNA) stock rose over 9% premarket after Bloomberg reported the company has been working on early-stage vaccines targeting hantaviruses.FinancialThe State Street Financial Select Sector SPDR ETF (XLF) retreated by 0.01%. Direxion Daily Financial Bull 3X Shares (FAS) was down 0.01%, while its bearish counterpart, Direxion Daily Financial Bear 3X Shares (FAZ), was 0.2% lower.ORIX (IX) shares were up more than 8% pre-bell after the company reported higher fiscal 2026 earnings and revenue.ConsumerThe State Street Consumer Staples Select Sector SPDR ETF (XLP) was up 0.2%, and the Vanguard Consumer Staples Index Fund ETF Shares (VDC) gained 0.04%. The iShares US Consumer Staples ETF (IYK) was flat. The State Street Consumer Discretionary Select Sector SPDR ETF (XLY) lost 0.3%. The VanEck Retail ETF (RTH) was down 0.4%, while the State Street SPDR S&P Retail ETF (XRT) retreated by 0.3%.United Parks & Resorts (PRKS) shares were down more than 3% pre-bell after the company reported a wider Q1 loss and lower revenue.IndustrialThe State Street Industrial Select Sector SPDR ETF (XLI) retreated by 0.2%, while the Vanguard Industrials Index Fund (VIS) was down 0.1%, and the iShares US Industrials ETF (IYJ) was inactive.Grupo Aeroportuario del Pacifico (PAC) stock was down more than 1% before the opening bell. The company said it had started the process for the potential establishment of a trust for the issuance of energy and infrastructure investment trust certificates, with a view to subscribing to a minority equity stake in the 12 Mexican airport concessionaires that Grupo Aeroportuario operates.EnergyThe iShares US Energy ETF (IYE) rose 1.8%, while the State Street Energy Select Sector SPDR ETF (XLE) was up by 1.3%.Cameco (CCJ) stock was down more than 1% before Monday's opening bell after the company said that flooding in northern Saskatchewan collapsed the Smoothstone River Bridge, disrupting a key supply route to its McArthur River mine and Key Lake mill.CommoditiesFront-month US West Texas Intermediate crude oil rose 2.6% to $97.91 per barrel on the New York Mercantile Exchange. Natural gas was up 2.5% at $2.83 per 1 million British Thermal Units. The United States Oil Fund (USO) advanced 3.9%, while the United States Natural Gas Fund (UNG) was 3.3% higher.Gold futures for May fell by 1% to $4,683.40 an ounce on the Comex. Silver futures advanced by 1.2% to $81.81 an ounce. SPDR Gold Shares (GLD) was 1.1% lower, and the iShares Silver Trust (SLV) rose by 0.6%.

Dow JonesNasdaq CompositeS&P 500$BETH$BITO$CCJ$EEM$EETH$EXI$FAS$FAZ$GLD$IBB$IGM$IGV$IPK$IVV$IWM$IX$IYE$IYH$IYJ$IYK$IYW$MNDY$MRNA$PAC$PMR$PRKS$QQQ$RTH$SLV$SOXX$SPY$UNG$USO$VDC$VHT$VIS$XLE$XLF$XLI$XLK$XLP$XLV$XLY$XRT$XSD
Sectors

Sector Update: Healthcare

Healthcare stocks were rising premarket Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.2% higher and the iShares Biotechnology ETF (IBB) up 0.4%.Moderna (MRNA) stock was up more than 8% after the company, as per Bloomberg, said it has been working on early-stage vaccines targeting hantaviruses.

$MRNA
Wire

Moderna Shares Jump 8% After Company Flags Early Hantavirus Vaccine Work

Moderna (MRNA) shares rose over 7% in Monday's premarket after the company, as per Bloomberg, said it has been working on early-stage vaccines targeting hantaviruses.The vaccine maker said its research is still at an early stage and had begun before recent infections were reported aboard the Dutch-flagged Hondius, according to Bloomberg. The work is being carried out with the U.S. Army Medical Research Institute of Infectious Diseases and the Korea University College of Medicine, the report said.Moderna said its broader strategy includes preparing for emerging health threats using its mRNA platform, which can be adapted more quickly than conventional vaccine technologies, the report added.Price: $58.43, Change: $+4.08, Percent Change: +7.51%

$MRNA
Sectors

Sector Update: Health Care Stocks Softer in Afternoon Trading

Health care stocks declined Monday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing 0.3%.The iShares Biotechnology ETF (IBB) rose 1.3%.In corporate news, Amgen (AMGN) said Monday it will invest an additional $300 million in its biologics manufacturing facility in Puerto Rico. Amgen shares were down 2.1%.Vanda Pharmaceuticals (VNDA) shares jumped past 5% after it said Monday its motion sickness drug Nereus is now commercially available in the US.Eli Lilly (LLY) shares added 0.2% after Barclays lifted the company's price target to $1,400 from $1,350, while keeping its overweight rating.Moderna (MRNA) is showing continued advancement across its pipeline, with progress in cancer vaccines and infectious disease programs supporting a more balanced risk-reward profile, RBC Capital Markets said in a note. RBC maintained its sector perform rating on the stock and raised its price target to $38 from $35. Moderna shares rose 4.6%.

$AMGN$LLY$MRNA$VNDA
Wire

Moderna Sees Progress Across Cancer Vaccine, Infectious Disease Pipeline, RBC Says

Moderna (MRNA) is showing continued advancement across its pipeline, with progress in cancer vaccines and infectious disease programs supporting a more balanced risk-reward profile, RBC Capital said in a Friday note.According to the note, Moderna's Q1 results were driven by a stronger-than-expected COVID franchise, largely supported by international revenue recognition, while management reaffirmed its full-year outlook across revenue, R&D, SG&A, and capital expenditures.RBC highlighted ongoing momentum in Moderna's infectious disease pipeline, including upcoming flu vaccine regulatory milestones, progress on a flu-COVID combination shot, and advancement of its norovirus program, with data expected later this year depending on case accruals.On oncology, RBC noted upcoming catalysts for Moderna, including potential Phase III adjuvant melanoma data, updated Phase II results at ASCO, and a new pivotal early-stage non-small cell lung cancer study using its cancer vaccine platform.RBC maintained its sector perform rating on the stock and raised its price target to $38 from $35.Shares of Moderna were up over 4% in Monday trading.Price: $47.57, Change: $+2.20, Percent Change: +4.85%

$MRNA

Showing 61-80 of 98

Track with the FINWIRES app suite